RADIOTHERAPY
JUST Leveled Up



Watch video

 

Turning cancer on
itself > Finally

SCINTIX® therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.

SELF-DRIVING RADIOTHERAPY

Cancer is talking.
We’re listening.

When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our machine uses to manage motion and treat solid tumors of any stage disease.

Learn About Emissions

Targeting Cancer

GOOD NEWS FOR ORGANS.
BAD NEWS FOR TUMORS.

Our SCINTIX technology delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.

Learn About Targeting

ANY STAGE TUMOR

A world where stage
is just a number.

Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.

Discover the Potential

Combination Treatment

Come at cancer
from every angle.

Treatment isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.

Learn About Treatment

Learn more about our breakthrough technology

SCINTIX Biology-guided Radiotherapy

By combining PET-CT and radiotherapy, we're able to find and treat cancer using emissions created by tumors themselves.

Clinicians

Discover SCINTIX therapy.

Cancer Centers

See how SCINTIX therapy can play a role
in your cancer program.

Make every day count

See Available Positions

Latest

Press Releases

CMS Assigns Accretive Reimbursement for RefleXion’s Breakthrough SCINTIX Therapy

New codes and payment expected to facilitate clinical adoption of novel cancer treatment option HAYWARD, Calif., Jan. 11, 2024 – RefleXion Medical, Inc., a therapeutic oncology company, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a national payment rate for RefleXion’s SCINTIX® biology-guided radiotherapy using CMS’ New Technology (NT) Ambulatory […]

View All Press chevron right

Blog

Oligometastatic Disease: An Overview

For patients battling cancer, little is more important than knowing exactly where they stand in the course of the disease. When a malignant tumor spreads from its original location to additional sites in the body, this means the disease has “metastasized.” If the disease has spread to many locations, this is sometimes termed polymetastatic disease. […]

View All Blog Posts chevron right

Feedback
and
Inquiries.

Let us tell you more.

Contact Us

Sign up for our
latest news and information.

Stay up to date.

Sign Up